Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine. It is a simplified analogue of noribogaine.
The drug acts as a potent serotonin 5-HT<sub>2A</sub> receptor partial agonist ( â 90nM; = 35%). It also has activity as a dopamine transporter (DAT) chaperone. Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. However, it does produce analgesic effects that can be diminished by the serotonin 5-HT<sub>2A</sub> receptor antagonist ketanserin. The drug shows relatively low expected bloodâÂÂbrain barrier permeability.
Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.